November 20, 2023 — Medtronic plc, a global leader in healthcare technology, announced that the United States Food and Drug Administration (FDA) has approved the Symplicity Spyral renal denervation ...
Renal Denervation
This channel includes news and new technology innovations for renal denervation used to treat hypertension. Renal denervation is a catheter-based therapy. The catheter is into the renal artery and delivers radio-frequency energy to ablate the nerves in the vessel wall that regulate vasoconstriction. This leaves the vessel permanently in the widest open position to allow greater blood flow to the kidneys. This enables greater filtration of the blood and removal of excess water that causes hypertension.
-
-
May 16, 2021 — Two months after undergoing renal denervation (RDN) with the ReCor Paradise renal denervation system, patients with high blood pressure who did not respond to treatment with multiple ...
-
April 1, 2020 — Three months after undergoing renal denervation (RDN), patients with untreated high blood pressure had statistically significant reductions in average blood pressure over 24 hours ...
-
Investigators unveiled late-breaking clinical data from a first-of-its-kind physician sponsored clinical trial at the 2019 EuroPCR Annual Meeting, May 20-23 in Paris, France. The data indicate that renal denervation (RDN) with the Medtronic Symplicity renal denervation system was associated with reduced occurrence of subclinical atrial fibrillation (AF) in a small subset of high-risk patients with hypertensive heart disease over a median follow-up period of more than two years.
At the Cardiovascular Research Technologies (CRT) 2025 conference in Washington, D.C., Medtronic presented new data and ...
March 10, 2025
Jan. 13, 2025 — Medtronic recently announced that the Centers for Medicare & Medicaid Services (CMS) is opening a ...
January 27, 2025
Jan. 13, 2025 — Medtronic plc recently announced that the Centers for Medicare & Medicaid Services (CMS) is opening a ...
January 14, 2025
November 20, 2023 — Medtronic plc, a global leader in healthcare technology, announced that the United States Food and ...
November 20, 2023
November 15, 2023 — Recor Medical, Inc. and its parent company, Otsuka Medical Devices Co., Ltd. announced the first ...
November 15, 2023
August 21, 2023 — The Society for Cardiovascular Angiography & Interventions (SCAI) has released a position statement on ...
August 21, 2023
March 2, 2023 — ReCor Medical, Inc. and its parent company, Otsuka Medical Devices Co., Ltd. announced that primary ...
March 02, 2023
January 9, 2023 — ReCor Medical, Inc. and its parent company, Otsuka Medical Devices Co., Ltd. announced the appointment ...
January 09, 2023
July 29, 2022 — ReCor Medical, Inc. and Otsuka Medical Devices Co., Ltd., a fully owned subsidiary of Otsuka Holdings ...
July 29, 2022
November 9, 2021 — Six-month outcomes from the randomized RADIANCE-HTN TRIO Trial comparing endovascular ultrasound ...
November 09, 2021
Feature | Hypertension | By Dave Fornell, Editor
May 16, 2021 — Two months after undergoing renal denervation (RDN) with the ReCor Paradise renal denervation system ...
May 16, 2021
December 9, 2020 — SoniVie, an Israeli company developing the Therapeutic Intra-Vascular Ultrasound (TIVUS) System to ...
December 09, 2020
June 26, 2020 – New data from the Global SYMPLICITY Registry (GSR) showed that renal denervation (RDN) with the ...
June 26, 2020
April 1, 2020 — Three months after undergoing renal denervation (RDN), patients with untreated high blood pressure had ...
April 01, 2020April 1, 2020 — Three months after undergoing renal denervation (RDN), patients with untreated high blood pressure had ...
April 01, 2020